ESR1 and breast carcinoma: Collectively, these findings suggest that ENDX attenuates AKT signaling primarily through attenuation of AKTSer473 phosphorylation in ERα+ breast cancer cells at clinically relevant 5 μM concentration, a unique effect not observed with other SERM’s at clinically relevant concentrations.